Skip to main content
. Author manuscript; available in PMC: 2016 Apr 27.
Published in final edited form as: Leuk Res. 2015 Feb 2;39(4):419–423. doi: 10.1016/j.leukres.2015.01.012

Table 2.

Incidence of primary myelofibrosis, post-PV MF, post-ET MF, JAK2 status, and transformation to leukemia for Chr12 and Non-Chr12 patients.

Characteristic Chr. 12 (n=31) Non-Chr. 12 (n=945) p-value
PMF, N (%) 15 (48) 685 (72) <0.01
PPMF, N (%) 11 (35) 137 (14) <0.001
PTMF, N (%) 5 (16) 123 (13) 0.11
JAK2-positive, N (%) [median allele burden % |range|] 18 (58) [69.7 (10.5-95.9)] 471 (50) [57.3 (1-99.1)] 0.55
JAK2-negative, N (%) 7 (23) 239 (25)
JAK2-unknown, N (%) 6 (19) 235 (25)
Transformation to leukemia, N (%) 1 (3) 76 (8) 0.660
Months to transformation to leukemia (range) 70.2 33.6 (1.1-315)

PMF, Primary myelofibrosis; PPMF, Post-polycythemia vera myelofibrosis; PTMF, Post-thrombocytosis myelofibrosis